Baochi Ou1, Jingkun Zhao1, Shaopei Guan1, Aiguo Lu2. 1. Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. 2. Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China. weichuang_lu@163.com.
Abstract
BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC), but little is known about the influence of IBD on CRC prognosis. AIMS: The aim of this study was to perform a meta-analysis to compare survival in CRC patients with IBD (IBD-CRC) and without IBD. METHODS: An electronic search was conducted via PubMed, Embase, and the Cochrane Library to identify eligible trials until July 2015. We pooled the hazard ratios (HRs) and their 95% confidence intervals (CIs) to quantitatively assess the survival of CRC in patients with or without IBD. In addition, clinicopathological parameters of IBD-CRC versus non-IBD CRC were evaluated. RESULTS: Twelve studies containing a total of 3472 IBD-CRC patients were eligible according to our selection criteria. Our analysis indicated that CRC patients with IBD had shorter overall survival than those without IBD (HR 1.24, 95% CI 1.19-1.29). IBD-CRC showed a propensity to develop in proximal colon [odds ratio (OR) 2.52, 95% CI 1.35-4.72] and correlated with worse differentiation of tumor (OR 1.59, 95% CI 1.26-1.99) compared to non-IBD CRC. Meta-regression analysis showed that sample size (P = 0.002) could explain 99.01% inter-study heterogeneity. CONCLUSION: This meta-analysis found poorer overall survival in CRC patients with IBD than CRC patients without IBD, and further prospective research to confirm these findings is warranted.
BACKGROUND:Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC), but little is known about the influence of IBD on CRC prognosis. AIMS: The aim of this study was to perform a meta-analysis to compare survival in CRC patients with IBD (IBD-CRC) and without IBD. METHODS: An electronic search was conducted via PubMed, Embase, and the Cochrane Library to identify eligible trials until July 2015. We pooled the hazard ratios (HRs) and their 95% confidence intervals (CIs) to quantitatively assess the survival of CRC in patients with or without IBD. In addition, clinicopathological parameters of IBD-CRC versus non-IBD CRC were evaluated. RESULTS: Twelve studies containing a total of 3472 IBD-CRC patients were eligible according to our selection criteria. Our analysis indicated that CRC patients with IBD had shorter overall survival than those without IBD (HR 1.24, 95% CI 1.19-1.29). IBD-CRC showed a propensity to develop in proximal colon [odds ratio (OR) 2.52, 95% CI 1.35-4.72] and correlated with worse differentiation of tumor (OR 1.59, 95% CI 1.26-1.99) compared to non-IBD CRC. Meta-regression analysis showed that sample size (P = 0.002) could explain 99.01% inter-study heterogeneity. CONCLUSION: This meta-analysis found poorer overall survival in CRC patients with IBD than CRC patients without IBD, and further prospective research to confirm these findings is warranted.
Authors: Justin A Maykel; Gonzalo Hagerman; Anders F Mellgren; Shelby Y Li; Karim Alavi; Nancy N Baxter; Robert D Madoff Journal: Dis Colon Rectum Date: 2006-07 Impact factor: 4.585
Authors: Eilis Foran; Megan M Garrity-Park; Coralie Mureau; John Newell; Thomas C Smyrk; Paul J Limburg; Laurence J Egan Journal: Mol Cancer Res Date: 2010-03-30 Impact factor: 5.852
Authors: Ane B Jensen; Mette Larsen; Mette Gislum; Mette V Skriver; Peter Jepsen; Bente Nørgaard; Henrik T Sørensen Journal: Am J Gastroenterol Date: 2006-06 Impact factor: 10.864
Authors: Susan L Gearhart; Hari Nathan; Timothy M Pawlik; Elizabeth Wick; Jonathan Efron; Andrew D Shore Journal: Dis Colon Rectum Date: 2012-03 Impact factor: 4.585
Authors: Thierry Delaunoit; Paul J Limburg; Richard M Goldberg; James F Lymp; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2006-03 Impact factor: 11.382
Authors: Renata D Peixoto; Artur R Ferreira; James M Cleary; João P Fogacci; João P Vasconcelos; Alexandre A Jácome Journal: J Gastrointest Cancer Date: 2022-03-14
Authors: Michaela Lang; Maximilian Baumgartner; Aleksandra Rożalska; Adrian Frick; Alessandra Riva; Michael Jarek; David Berry; Christoph Gasche Journal: Int J Cancer Date: 2020-05-18 Impact factor: 7.396